Unexpected ethical dilemmas in sex assignment in 46,XY DSD due to 5-alpha reductase type 2 deficiency
- PMID: 28544750
- PMCID: PMC5489130
- DOI: 10.1002/ajmg.c.31560
Unexpected ethical dilemmas in sex assignment in 46,XY DSD due to 5-alpha reductase type 2 deficiency
Abstract
Sex assignment at birth remains one of the most clinically challenging and controversial topics in 46,XY disorders of sexual development (DSD). This is particularly challenging in deficiency of 5-alpha reductase type 2 given that external genitalia are typically undervirilized at birth but typically virilize at puberty to a variable degree. Historically, most individuals with 5-alpha reductase deficiency were raised females. However, reports that over half of patients who underwent a virilizing puberty adopted an adult male gender identity have challenged this practice. Consensus guidelines on assignment of sex of rearing at birth are equivocal or favor male assignment in the most virilized cases. While a male sex of rearing assignment may avoid lifelong hormonal therapy and/or allow the potential for fertility, female sex assignment may be more consistent with external anatomy in the most severely undervirilized cases. Herein, we describe five patients with 46,XY DSD due 5-alpha-reductase type 2 deficiency, all with a severe phenotype. An inter-disciplinary DSD medical team at one of two academic centers evaluated each patient. This case series illustrates the complicated decision-making process of assignment of sex of rearing at birth in 5-alpha reductase type 2 deficiency and the challenges that arise when the interests of the child, parental wishes, recommendations of the medical team, and state law collide.
Keywords: 5-alpha reductase deficiency; 5aR2D; DSD; SRD5A2; ethics; gender; sex assignment.
© 2017 Wiley Periodicals, Inc.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Comment in
-
Re: Unexpected Ethical Dilemmas in Sex Assignment in 46,XY DSD Due to 5-Alpha Reductase Type 2 Deficiency.J Urol. 2018 Oct;200(4):685-687. doi: 10.1016/j.juro.2018.07.005. Epub 2018 Jul 12. J Urol. 2018. PMID: 30227559 No abstract available.
References
-
- Berra M, Williams EL, Muroni B, Creighton SM, Honour JW, Rumsby G, Conway GS. Recognition of 5α-reductase-2 deficiency in an adult female 46XY DSD clinic. Eur J Endocrinol. 2011;164(6):1019–25. - PubMed
-
- Cohen-Kettenis PT. Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav. 2005;34(4):399–410. - PubMed
-
- Costa EM, Domenice S, Sircili MH, Inacio M, Mendonca BB. DSD due to 5α-reductase 2 deficiency - from diagnosis to long-term outcome. Semin Reprod Med. 2012;30(5):427–31. - PubMed
-
- Disability Rights Washington. Devaluing people with disabilities: medical procedures that violate civil rights – 2012. Retrieved from: http://www.disabilityrightswa.org/devaluing-people-disabilities.
-
- Douglas G, Axelrad ME, Brandt ML, Crabtree E, Dietrich JE, French S, Gunn S, Karaviti L, Lopez ME, Macias CG, McCullough LB, Suresh D, Sutton VR. Consensus in Guidelines for Evaluation of DSD by the Texas Children’s Hospital Multidisciplinary Gender Medicine Team. Int J Pediatr Endocrinol. 2010;2010:919707. - PMC - PubMed
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources